Max Healthcare Institute LtdQ4 FY25
Max Healthcare Institute Ltd Q4 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹1,081P/E: 70.0Market Cap: ₹1.0L CrSector: Healthcare Services
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- →Network gross revenue grew 16% YoY for the nine months ended Dec 2023; Q3 revenue grew 14% YoY.
- →Average Revenue Per Occupied Bed (ARPOB) is expected to grow reasonably at 9-10% driven by price increases, OPD growth, oncology growth, and improved case/channel mix.
- →International patient revenue grew 25% YoY, supporting revenue growth.
- →Expansion adding around 800-1000 beds over next 5-6 years expected to be quickly absorbed due to high demand and occupancy constraints.
- →Brownfield expansions like Shalimar Bagh show new beds ramp up quickly and contribute positive EBITDA and operating margins.
- →Oncology, including robotics and immunotherapy, is a key growth driver, with higher EBITDA per bed.
- →Institutional business tariffs may be revised upwards, potentially increasing revenue.
- →Seasonal patterns: Q2 & Q4 typically strongest quarters.
- →Overall, a robust Q4 is expected due to seasonality and continued growth momentum.
Margin guidance
Category 3- →Max Healthcare expects a robust Q4, benefiting from seasonality effects (Q2 and Q4 are typically strongest).
- →Existing hospitals are expected to see continued revenue growth and operating leverage, with around 7% cost growth.
- →New hospital beds (about 8% capacity increase) will start with lower ARPOB and negative EBITDA, breakeven expected within 6-12 months, which could temporarily temper margin expansion.
- →EBITDA per bed is improving, with a 15% increase noted recently, driven by case mix, ARPOB increases, and operating leverage.
- →Institutional business shows strong ARPOB growth (about 9-10%), and oncology and international patient growth remain key drivers.
- →Margin improvement may be stable to moderate in FY25, balanced between mature hospital growth and new hospital ramp-ups.
- →Overall, earnings growth will continue but moderated by new capacity commissioning costs.
3 more insights locked — sign up free to unlock
Fundraise plans
- →There is no explicit mention of any current or immediate new fundraising through debt or equity in the provided pages.
- →The company highlights strong free cash flow generation (Rs. 924 crore over nine months), which is being used for expansion and dividends.
- →Expansion projects (Dwarka, Nanavati, Gurgaon, Mohali, Saket Complex) are largely funded through internal cash flows, with no indication of new external financing.
- →Abhay Soi mentioned having sufficient wherewithal to add 3-4 hospitals within 1-2 years without stressing the balance sheet.
- →For Lucknow, large-scale future capacity expansions post FY28 are described as potential, with no approved CAPEX or Board approvals currently.
- →Overall, the company appears financially comfortable funding growth organically without aggressive external fundraising plans at this time.
Order book
- →No explicit mention of current or expected order book or pending orders was found in the provided transcript excerpts.
- →The discussion primarily focuses on expansion projects, hospital bed capacity, acquisitions (e.g., Lucknow hospital), and operational performance.
- →Capex updates note Rs. 300 crore spent in nine months FY24 against a Rs. 900 crore guidance, with multiple hospitals (Dwarka, Nanavati, Gurgaon, Mohali) expected to commission in FY25.
- →No detailed order book figures or pending order specifics related to contracts or procurement are disclosed in the text.
- →Expansion involves organic growth and opportunistic acquisitions, with active but not aggressive pursuit of opportunities in new cities.
Capex plans
Yes- Dwarka hospital (300 beds): Near commissioning; asset-light model with lease contract; minimal future CAPEX expected; finishing in progress.
- Nanavati (329 beds): Basement and ground level completed; steel fabrication started; on schedule.
- Sector-56 Gurgaon (300 beds): Structural drawing approved; RCC works commenced; on schedule.
- Mohali (190 beds): Design finalized; base raft concrete started; on schedule.
- Max Smart (Saket Complex, 350 beds): Tree transplantation underway; existing structures demolished; project progressing after initial delay.
- Max Vikrant (Saket Complex, 300 beds): Revised building plans submitted; infrastructure dues paid; contractor tenders under review; Forest department NOC applied.
- Expected CAPEX for FY24 is Rs. 900 crore (tracking Rs. 300 crore so far).
- Lucknow expansion has land for significant future capacity (up to 3500 beds possible post-2028); construction and expansion will be phased.
- Brownfield expansions like Shalimar Bagh are preferred for quicker bed additions with better operating leverage.
Overall, multiple large-scale projects are underway with planned commissioning over next 1-3 years and further strategic expansions contemplated.
How does Max Healthcare Institute Ltd rank vs peers in Healthcare Services?
Pro feature1Max Healthcare Institute Ltd
Rev 3Mar 3
See full Healthcare Services sector rankings
Want more stocks like Max Healthcare Institute Ltd?
Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.
Build my portfolio